Mutational profiling of cfDNA verified CRC‐related mutations in 11 of 35 (31%) corresponding plasma samples (Figure 2), including 2 of 10 (20%) BRAF and 9 of 25 (36%) KRAS mutations. Here, KRAS is linked to colorectal carcinoma.